RBC Capital, Truist Securities, and UBS have all increased their price targets for Vertex Pharmaceuticals, reflecting a revised valuation outlook for the biotechnology company. RBC Capital analyst Brian Abrahams maintained an Outperform rating while raising the target to $570 from $543. Separately, Truist Securities analyst Danielle Brill kept a Buy rating and lifted the target to $560 from $542. Additionally, UBS analyst Michael Yee maintained a Buy rating and raised the price target from $545 to $585.

Vertex Pharmaceuticals is listed on NASDAQ under the ticker symbol VRTX. The adjustments reinforce the firms' positive stances on the stock.

Vertex Pharmaceuticals Incorporated will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss its performance for the quarter. Investors and analysts can access the live webcast through the "Investors" section of Vertex's website at www.vrtx.com .

To participate via phone, U.S. callers should dial (833) 630-2124, while international callers can reach the conference at +1 (412) 317-0651. Participants must reference the "Vertex Pharmaceuticals Second Quarter 2026 Earnings Call" when joining. The company recommends registering at least 15 minutes prior to the scheduled start time to ensure a timely connection. An archived version of the webcast will be available on the company's website following the event.

Conference Call Details

Vertex is a global biotechnology company focused on creating transformative medicines for serious diseases. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. Its clinical pipeline includes investigational therapies for conditions such as IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, and type 1 diabetes. Founded in 1989, Vertex has its global headquarters in Boston and international headquarters in London.